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A B S T R A C T
There are few randomized trials comparing filgrastim and pegfilgrastim in peripheral blood
stem cell mobilization (PBSCM). None of the trials studied the effects of the timing of
pegfilgrastim administration on the outcomes of mobilization. We conducted a random-
ized triple blind control trial comparing the outcomes of filgrastim 5 μg/kg daily from day
3 onwards, ‘early’ pegfilgrastim 6 mg on day 3 and ‘delayed’ pegfilgrastim 6 mg on day 7
in cyclophosphamide PBSCM in patients with no previous history of mobilization. Periph-
eral blood (PB) CD34+ cell count was checked on day 8 and day 11 onward. Apheresis was
started when PB CD34+ ≥ 10/μl from day 11 onward. The primary outcome was the suc-
cessful mobilization rate, defined as cumulative collection of ≥2 × 106/kg CD34+ cells in three
or less apheresis. The secondary outcomes were the day of neutrophil and platelet en-
graftment post transplantation. There were 156 patients randomized and 134 patients’ data
analyzed. Pegfilgrastim 6 mg day 7 produced highest percentage of successful mobiliza-
tion, 34 out of 48 (70.8%) analyzed patients, followed by daily filgrastim, 28 out of 44 (63.6%)
and day 3 pegfilgrastim, 20 out of 42 (47.6%) (p = 0.075). Pegfilgrastim day 7 and daily
filgrastim reported 1.48 (p = 0.014) and 1.49 (p = 0.013) times higher successful mobiliza-
tion rate respectively as compared to pegfilgrastim day 3 after adjusting for disease, gender
and exposure to myelotoxic agent. Multiple myeloma patients were three times more likely
to achieve successful mobilization as compared to acute leukemia or lymphoma patients.
Pegfilgrastim avoided the overshoot of white cells compared to filgrastim. There was no
difference in the duration of both white cells and platelet recovery post transplantation
between the three interventional arms.
© 2015 Elsevier Ltd. All rights reserved.
This trial was registered with National Medical Research Registry as NMRR-10–755-6906.
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